目的：基于癌症基因组图谱(TCGA)数据库分析SLC52A2与葡萄膜黑色素瘤(UM)的相关性，初步探讨SLC52A2对UM患者预后的影响及可能的机制。

方法：通过TCGA数据库下载收集80例UM患者的临床信息资料和SLC52A2的mRNA表达数据，根据SLC52A2表达量采用中位数法将80例患者分为SLC52A2高、低表达组，分析SLC52A2的表达水平与患者临床病理特征及预后的关系。对患者的年龄、性别、临床分期、病理分期、SLC52A2的mRNA表达进行Cox单因素和多因素分析，寻找UM预后因子。GSEA富集分析预测SLC52A2在UM中可能的调控通路。

结果：SLC52A2低表达患者生存预后优于SLC52A2高表达患者(P<0.05)。SLC52A2高、低表达组患者的年龄、性别、临床分期、病理分期均无差异(P>0.05)。Cox多因素分析表明，SLC52A2高表达是UM患者预后的危险因素。结合SLC52A2表达和临床病理学特征开发的列线图预测模型，可较为准确地预测UM患者的生存概率。SLC52A2高、低表达组Th2细胞、Treg细胞的浸润丰度分别比较有差异(均P<0.001)。GSEA分析表明，SLC52A2高表达的组织中存在JAK-STAT信号通路(FDR=0.028，P=0.004)和PI3K/AKT信号通路(FDR=0.017，P=0.002)相关基因富集。

结论：SLC52A2高表达是UM患者预后的危险因素。SLC52A2可作为UM预后相关的生物标志物，有望成为UM治疗的新靶点。

METHODS: The clinical information on 80 patients with UM and mRNA expression data of SLC52A2 were collected from TCGA database. According to the expression level of SLC52A2, 80 patients were divided into high and low expression groups by median method. The relationship between the expression of SLC52A2 and clinical pathological features, as well as the prognosis was analyzed. The age, sex, clinical stage, pathological stage, and mRNA expression of SLC52A2 were analyzed by univariate and multivariate Cox analysis to search the prognostic factors of UM. Enrichment analyses were used to predict the possible regulatory pathway of SLC52A2 in UM.

RESULTS: The survival prognosis of patients with low expression of SLC52A2 was better than that of patients with high expression of SLC52A2(P<0.05). The level of SLC52A2 has no significant correlation with the age, sex, clinical stage, and pathological stage of patients in both groups(P>0.05). Multivariate Cox analysis showed that the high expression of SLC52A2 was a risk factor for poor prognosis. The nomogram prediction model developed by combining the expression of SLC52A2 with clinical pathological features could accurately predict the survival probability of UM patients. The infiltration abundance of Th2 and Treg cells in both groups has difference(all P<0.001). GSEA analysis showed that the gene of JAK-STAT(FDR=0.028, P=0.004)and PI3K/AKT(FDR=0.017, P=0.002)were rich in samples with high expression of SLC52A2.

CONCLUSION: The high expression of SLC52A2 is a risk factor for the prognosis of UM patients. SLC52A2 can be used as a biomarker to predict the prognosis and to become a new target for the treatment of patients with UM.